DNP and two other companies establish a joint venture to advance regenerative medicine
Dai Nippon Printing Co., Ltd. (DNP) has announced the establishment of a new joint venture, "TriNebula Cell Tech," in partnership with the South Korean biotech firm NEXEL and CMIC Pharma Science. The new company was established on October 9, 2026.
The establishment of this joint venture is driven by the rapid growth in technological development within the field of regenerative medicine, which has been attracting significant attention in recent years. By combining their respective strengths, the three companies aim to accelerate the development of cell-based therapeutic technologies and related research.
Specifically, by integrating NEXEL's cell manufacturing technology, CMIC Pharma Science's expertise in pharmaceutical development support, and Dai Nippon Printing's manufacturing and production technologies, the venture plans to build a system capable of stably providing high-quality cell products.
This initiative is expected to contribute to the development of new treatments and support medical practice in the future. Moving forward, the three companies intend to work together to pioneer new markets in regenerative medicine and contribute to the improvement of public health.